Amarin (NASDAQ:AMRN) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.04, Yahoo Finance reports. The business had revenue of $143.28 million for the quarter, compared to analysts’ expectations of $137.70 million. Amarin had a negative return on equity of 8.28% and a negative net margin of 5.27%. The company’s revenue for the quarter was up 85.3% compared to the same quarter last year. During the same period last year, the firm earned ($0.09) earnings per share. Amarin updated its FY 2020
After-Hours guidance to EPS.
Shares of NASDAQ AMRN remained flat at $$14.67 during mid-day trading on Friday. 12,122,441 shares of the company were exchanged, compared to its average volume of 7,693,983. Amarin has a fifty-two week low of $13.67 and a fifty-two week high of $26.12. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.45 and a current ratio of 3.69. The firm has a market capitalization of $5.24 billion, a price-to-earnings ratio of -209.54 and a beta of 1.07. The company has a fifty day moving average of $18.72 and a two-hundred day moving average of $18.23.
Several analysts have recently issued reports on the company. BidaskClub upgraded Amarin from a “strong sell” rating to a “sell” rating in a research note on Wednesday. ValuEngine raised Amarin from a “hold” rating to a “buy” rating in a report on Monday, February 3rd. JPMorgan Chase & Co. started coverage on Amarin in a report on Monday, January 6th. They set a “neutral” rating and a $22.00 price objective for the company. TheStreet upgraded Amarin from a “d” rating to a “c-” rating in a report on Friday, November 15th. Finally, HC Wainwright reaffirmed a “positive” rating and set a $51.00 price target on shares of Amarin in a report on Wednesday. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $27.00.
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.
Recommended Story: Price to Earnings Ratio (PE) Basics
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.